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Abstract
Background: The increase in recent outbreaks and unpredictable changes of highly pathogenic avian influenza (HPAI) H5N1
in birds and humans highlights the urgent need to develop a cross-protective H5N1 vaccine. We here report our
development of a multiple-clade H5N1 influenza vaccine tested for immunogenicity and efficacy to confer cross-protection
in an animal model.
Methodology/Principal Findings: Mice received two doses of influenza split vaccine with oil-in-water emulsion adjuvant
SP01 by intranasal administration separated by two weeks. Single vaccines (3 mg HA per dose) included rg-A/Vietnam/1203/
2004(Clade 1), rg-A/Indonesia/05/2005(Clade 2.1), and rg-A/Anhui/1/2005(Clade 2.3.4). The trivalent vaccine contained 1 mg
HA per dose of each single vaccine. Importantly, complete cross-protection was observed in mice immunized using trivalent
vaccine with oil-in-water emulsion adjuvant SP01 that was subsequently challenged with the lethal A/OT/SZ/097/03
influenza strain (Clade 0), whereas only the survival rate was up to 60% in single A/Anhui/1/2005 vaccine group.
Conclusion/Significance: Our findings demonstrated that the multiple-clade H5N1 influenza vaccine was able to elicit a
cross-protective immune response to heterologous HPAI H5N1 virus, thus giving rise to a broadly cross-reactive vaccine to
potential prevention use ahead of the strain-specific pandemic influenza vaccine in the event of an HPAI H5N1 influenza
outbreak. Also, the multiple-clade adjuvanted vaccine could be useful in allowing timely initiation of vaccination against
unknown pandemic virus.
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Introduction
Influenza infection continues to be a major threat to human
health on several fronts. Influenza A (H5N1) viruses remain a
major concern due to their evolution, genetic diversity, broad host
range, and ongoing circulation in wild and domestic birds
worldwide. As of 29 Nov. 2011, the World Health Organization
(WHO) has reported 571 laboratory-confirmed cases of human A/
H5N1 infections, resulting in 335 deaths (http://www.who.int/csr/
disease/avian_influenza/country/cases_table_2011_01_20/en/index.html).
The high observed mortality is a typical feature of this human
disease [1]. During the spring of 2009, the emerging swine-
origin H1N1 influenza viruses (S-OIVs) are being detected in
almost all countries in the world, and their global spread would
undoubtedly result in a considerable number of infected
individuals [2,3]. Importantly, a great concern exists that the
reassortants between avian H5N1 and influenza A (H1N1),
seasonal viruses or changing receptor binding specificity of H5
might be of great impact to human health, once it acquires the
capability of human-to-human transmission [4]. Moreover, in
the event of a new influenza virus, we cannot predict the strain
that will cause the pandemic.
To date, vaccines remain the cornerstone of influenza control.
Outbreaks and the pandemic potential of H5N1 viruses have led
to stockpiling of H5N1 pre-pandemic inactivated vaccines for
human use in many countries. In the face of a highly pathogenic
avian influenza (HPAI) H5N1 influenza virus, an update of
current and completed vaccine clinical trials can be found on the
WHO website (http://www.who.int/vaccine_research/diseases/
influenza/flu_trials_tables/en/index.html). The stockpiling of a panel
of vaccines with hemagglutinin (HA) antigenic variations, includ-
ing A/Vietnam/1203/2004(VN), A/Vietnam/1194/2004(VN), A/
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30252Indonesia/05/2005(ID), and A/Anhui/1/2005(AH) vaccine viruses,
were recommended by the WHO for vaccine development [5].
The H5N1 influenza viruses are currently divisible into clades (0
to 9) on the basis of phylogenetic analysis of their hemagglutinin
(HA) genes. The viruses circulating and characterised from 16
February 2011 to 19 September 2011 belonged to the following
clades, Clade 1.1 (previously part of clade 1), Clade 2.2.1, Clade
2.2.1.1 (previously part of clade 2.2.1), Clade 2.2.2 (previously
part of clade 2.2), Clade 2.3.2.1 (previously part of clade 2.3.2),
Clade 2.3.4, Clade 2.3.4.2 (previously part of 2.3.4) [5]. Taken
together, most currently circulating H5N1 strains that have
infected humans still belong to four serologically distinct
antigenic groups (clades 1, 2.1, 2.2, and 2.3.4) [6]. Previous
work demonstrated that the multiple-clade vaccine with MF59
adjuvant increased clade-specific and cross-clade antibody
responses against lethal challenge with clade 1 and 2 viruses
[7]. Although clade 0 was the least frequently seen, during the
summer and early fall of 1996, an outbreak of disease with 40%
morbidity occurred on a goose farm in Guangdong province,
China. The pathogen was isolated and termed A/Goose/
Guangdong/1/96(Gs/Gd/1/96) in clade 0. This virus was
transmitted to humans and caused deaths [8,9]. Here, it was
unknown if the multiple-clade vaccine based on clade 1 and 2 could
provide enough protection against lethal challenge to other clade
viruses, such as clade 0, which caused outbreaks in poultry in Hong
Kong and was transmitted to humans and caused deaths.
In the present study, we prepared three single H5N1 vaccines,
intranasally (i.n.) immunized mice with each vaccine or a trivalent
H5N1 influenza split vaccine including clade 1, 2.1 and 2.3.4
viruses of stockpile vaccines with an oil-in-water emulsion adjuvant
SP01, and then challenged with heterologus HPAI virus A/OT/
SZ/097/03 virus (clade 0) isolated from an ostrich to investigate
the immune responses, cross reactivity and a broader cross-
protection efficacy in a mouse model.
Results
Comparison of the functional efficacy of vaccine groups
by hemagglutination inhibition (HI) assays in serum from
immunized mice
Sera collected at pretest and 14 days after the first and second
doses of vaccine were assayed for the presence of H5N1 influenza-
specific antibodies using a HI assay. As shown in Figure 1, at 14
days after the last immunization, the HI titers of the hyper-
immune sera from mice immunized with VN/1203(Clade 1), ID/
05(Clade 2.1), and AH/01 (Clade 2.3.4) against homologous
viruses, reached 1:125, 1:400, and 1:480, respectively. Whereas,
the trivalent vaccine elicited humoral immune responses with HI
titers reaching 1:90 against VN/1203, 1:220 against ID/05, 1:260
against AH/01, and 1:185 against China097. Additionally, the
results revealed that mice immunized with trivalent vaccine
showed a significant rise (P,0.05) of the HI titer against VN/
1203, ID/05, AH/01, respectively. Moreover, a significant
differrence (P,0.01) was found in the trivalent vaccine against
China097 compared to PBS or oil-in-water emulsion groups on
day 28. Also, serum from mice vaccinated with single or trivalent
vaccine did not have any significant difference on the HI titer over
pre-vaccination on day 14 after the primary immunization.
Figure 1. HAI titers of mice immunized with single or trivalent H5N1 influenza split vaccines. Mice were immunized i.n. with single H5N1
influenza split vaccines (3 mg HA per dose) and a trivalent vaccine that contained 1 mg HA per dose of each single vaccine in combination with
adjuvant on day 0 and 14, and bled on day 28. Four HA units of VN/1203 (Fig. 1A), ID/05 (Fig. 1B), AH/01 (Fig. 1C), and China097 (Fig. 1D) viral antigen
were used. Results are the geometric mean titers of positive sera (HI titer .10). The values are means 6 SEM from six mice. * p,0.05 and ** p,0.01.
The dashed horizontal line indicates the lower limit of detection.
doi:10.1371/journal.pone.0030252.g001
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enzyme-linked immunosorbent assay (ELISA)
We performed enzyme-linked immunosorbent assays (ELISA) to
investigate whether A H5N1 IgA antibodies are present in the
mucosal lavage from mice immunized with two doses of a single or
trivalent vaccine. In the immunized groups, anti-H5 IgA antibody
titers were detected in nasal and lung lavage fluids using ELISA
plates coated with purified H5N1 virus antigens 28 days post-
immunization. As shown in Figure 2, mice immunized nasally with
a single or trivalent vaccine produced mucosal IgA responses, and
sIgA antibodies could be detected in nasal and lung lavage fluids,
whereas no antibodies were detected in the PBS or oil-in-water
emulsion SP01groups.The results showedthat the trivalent vaccine
could induce mucosal responses with sIgA titers in lung lavage
reaching 1:66 against VN/1203, 1: 80 against ID/05, and 1:150
against AH/01, which were all lower than with a single vaccine
against homologous virus. Moreover, trivalent vaccine against VN/
1203, ID/05, or AH/01 significantly enhanced (P,0.01) the HA
specific mucosal IgA titer in lung lavage fluids other than against
homologous virus coated, whereas sIgA antibody response against
the H5N1 virus did not have any significant difference in nasal
lavage on day 28. Meanwhile, intramuscularimmunization with the
H5N1 single or trivalent vaccine failed to induce mucosal antibody
responses (data not shown). Thus, an intranasal administration
route enhances the efficiency of mucosal antibody production in
response to H5N1 vaccination.
Antibody secreting cell (ASC) response and cytokine
assays
No influenza-specific ASCs were detected prior to vaccination.
IgA antibody classes dominated the influenza H5N1-specific ASC
responses after two doses of the vaccine. As shown in Figure 3A,
numbers of ASCs significantly (P,0.05) decreased in mice
immunized with trivalent vaccine compared with VN/1203, ID/
05, AH/01 single vaccine on day 28 following immunization.
Higher numbers of IgA influenza-specific ASCs (ranging from 10
to 90 per 500,000 lymphocytes) were detected on day 28 after the
first immunization in spleen lymphocytes of BALB/c mice. With
respect to serum IgA responses, little IgA was detected after
vaccination (data not shown).
Two weeks after the last immunization, cytokine-producing cell
profiles from splenocytes of five mice per group were examined
using in vitro stimulation with antigen or RPMI-1640 medium as a
negative control. The spot number in each well was calculated on
an ELISPOT spot counter. As shown in Figure 3B and 3C,
trivalent vaccines induced significant (P,0.01) IFN-c-producing
cells compared to ID/05 or AH/01 single vaccine in immunized
BALB/c mice, while only the ID/05 single vaccine group induced
significant (P,0.05) specific IL-4-producing cells compared to
trivalent vaccines group. In addition, as a stimulus control,
splenocytes from each group could not produce IFN-c or IL-4
while stimulate in vitro with RPMI-1640 medium.
Protection against challenge with the lethal A/OT/SZ/
097/03 (H5N1) virus
The protective characteristics of standard immunization were
tested in an in vivo experiment. We concentrated on the possibility
that these single and trivalent vaccines could induce cross
protection against the lethal A/OT/SZ/097/03 (H5N1) virus
(clade 0). The challenge was made 2 weeks after the last
immunization using a lethal clade 0 influenza virus and viral
progression was monitored for 14 days. To determined whether
intranasal trivalent H5N1 vaccination could elicit protection
against lethal cross-infection, immunized mice (n=10/group)
were challenged i.n. with a 50LD50 (LD50 is the dose that causes
the death of 50% of test animals) OT/SZ/097/03 H5N1 strain 2
weeks after the boost immunization, and percent survival was
recorded. Varying decreases in body weight of the different groups
indicated the progress of the infection. In Figure 4A, vaccinated
mice were also resistant to lethal challenges with the HPAI H5N1
virus strains, whereas the control animals that received PBS or oil-
in-water emulsion adjuvant alone showed clinical signs of severe
disease and significant body weight loss starting on day 2 after
virus inoculation; they died or reached the humane euthanasia
endpoint 7–10 days after challenge. In contrast, all mice
immunized with trivalent vaccine remained alive at 14 days after
the challenge. Only a transient body weight loss was noted on day
8, but the animals recovered completely during the following
week. As shown in Figure 4B, the mortality figures show that the
trivalent vaccine provided 100% protection against the OT/SZ/
097/03 H5N1 strain while VN/1203, ID/05, and AH/01 vaccine
groups provided 30%, 40%, and 60% protection, respectively. Of
note, on 4 day post challenge, the group immunized with PBS or
oil-in-water emulsion adjuvant SP01 alone showed marked
damage to the lung parenchyma, strong lymphocyte infiltration,
and slight hemorrhages. A considerably better situation was found
in mice immunized using the trivalent vaccine with oil-in-water
emulsion adjuvant SP01 (Fig. 5A).
Figure 2. Mucosal antibody response in BALB/c. Secretion of anti-HA IgA antibodies against VN/1203, ID/05, and AH/01 H5N1 inactivated
antigen in nasal and lung lavage (dilution 1:5) from mice immunized i.n. with single H5N1 influenza split vaccines (3 mg HA per dose) and a trivalent
vaccine containing 1 mg HA per dose of each single vaccine in combination with adjuvant. The values are means 6 SEM from six mice. * p,0.05 and
** p,0.01. The dashed horizontal line indicates the lower limit of detection.
doi:10.1371/journal.pone.0030252.g002
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immunized mice
We investigated whether intranasal immunization with the VN/
1203, ID/05, AH/01, and trivalent vaccines could prevent local
replication of the OT/SZ/097/03 H5N1 virus in the respiratory
tract and systemic spread to the internal organs and brain tissue.
Mice (n=6/group) vaccinated twice with VN/1203, ID/05, AH/
01, or trivalent vaccines were challenged with the 50LD50 OT/
SZ/097/03 H5N1 strain, and animals were euthanized on day 4
post challenge. Nasal turbinates, lungs, spleen, kidney and brains
were collected to quantify the presence of the wt OT/SZ/097/03
virus. Viral titers in nasal turbinates and lungs were reduced
significantly (P,0.01) in the group vaccinated with the trivalent
vaccine combined with oil-in-water emulsion adjuvant SP01 as
compared to the groups administered PBS or adjuvant alone.
Moreover, ID/05 and AH/01 vaccine groups had differing
degrees of reduction (P,0.01) in nasal turbinates and lungs as
compared to placebo. In addition, viral titers in the brain of
immunized mice were undetectable in that of all vaccine groups.
Meanwhile, no wt virus could be detected in the spleen and kidney
of immunized mice and control animals (Fig. 5B). Thus, our results
show that immunization with VN/1203, ID/05, AH/01, or
trivalent vaccines decreases viral titers in the lungs and prevents
systemic spread of the OT/SZ/097/03 H5N1 virus in mice.
Discussion
The increased incidence of human infection with HPAI H5N1
viruses and associated high mortality rates has served as an alarm
for the global community. The problem not only concerns the
efficacy of the licensed types of influenza vaccines, but also the
time and capacity of the world industry to produce sufficient doses
of any influenza vaccine for stockpiling. New influenza vaccina-
tions strategies are urgently needed due to uncertainties regarding
drift and shift in HPAI viral strains. For, at least 6 months are
likely to elapse in face of an influenza pandemic and the initial
available of a strain-specific vaccine. An efficient pandemic
stockpile vaccine should be capable of inducing cross protection
against hypothetical viruses that have not yet spread in the human
population. A few results showed after receiving a cross-reactive
H5N1 influenza vaccine, individuals may require some immunity
to protect from lethal challenge of other clade HPAI H5N1 virus.
And after immunizing with a cross-reactive H5N1 influenza
vaccine, individuals may require only a single dose of strain-
specific pandemic vaccine [7,10,11].
The HA sequences of avian H5N1 viruses have diverged into
ten distinct phylogenetic clades (genetic groups). Genetic diver-
gence into clades also correlated with antigenic drift and often
antibodies generated against one clade do not efficiently inhibit or
neutralize a virus from another clade. Some clades have evolved
Figure 3. sIgA-ASC, INF-c, and IL-4 after vaccination as
examined by ELISPOT assay. Mice were immunized twice at a 2-
week interval with single H5N1 influenza split vaccines (3 mg HA per
dose) and a trivalent vaccine that contained 1 mg HA per dose of each
single vaccine in combination with adjuvant. On day 14 after the final
immunization, pools of three mice for each group were killed and
single-cell suspensions were prepared from spleen for the ELISPOT
assay. (A) The figure shows antibody-secreting cells (ASCs) per 500,000
lymphocytes. The bars indicate the mean number of specific ASCs per
500,000 lymphocytes 6 SD. (B) The INF-c and IL-4 secreted by spleen
lymphocytes were detected using ELISPOT after culture for 40–44 h.
The values are means 6 SEM from two experiments. * p,0.05 and **
p,0.01.
doi:10.1371/journal.pone.0030252.g003
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were immunized i.n. with single H5N1 influenza split vaccines (3 mg HA per dose) and a trivalent vaccine that contained 1 mg HA per dose of each
single vaccine in combination with adjuvant and challenged i.n. with 50LD50 OT/SZ/097/03 virus suspension. Mice were monitored for weight change
(A) and survival rates (B) throughout a 14-day observation period.
doi:10.1371/journal.pone.0030252.g004
Figure 5. Histopathological changes in lungs and virus titers of infected mice. Mice (n=6/group) immunized twice i.n. with single H5N1
influenza split vaccines (3 mg HA per dose) and a trivalent vaccine that contained 1 mg HA per dose of each single vaccine in combination with
adjuvant were infected with 50LD50 OT/SZ/097/03 virus 2 weeks after the second immunization. (A) Histopathological changes in the lungs on 4 day
post challenge. The figure indicates the representative images of histopathological damage from H & E-stained lungs of 5 mice in PBS group and
trivalent vaccine group. (magnification, 1006). (B) On day 4 after virus inoculation, mice were killed and the nasal turbinates, lungs, spleen, kidney,
and brains were collected. Virus titers in tissue homogenates were determined by TCID50 assay using MDCK cells. The values are means 6 SEM from
six mice. * p,0.05 and ** p,0.01. The dashed horizontal line indicates the lower limit of detection.
doi:10.1371/journal.pone.0030252.g005
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currently circulating H5N1 strains that have infected humans
belong to four serologically distinct antigenic groups (clades 1, 2.1,
2.2, and 2.3.4) [10]. However, in 1997, the HPAI H5N1 virus was
transmitted directly from chickens to humans and killed 6 of 18
infected people in Hong Kong [12]. Between 2003 and 2005,
outbreaks of the H5N1 virus occurred in poultry in East Asian
countries, and once again transmission of infection from birds to
humans resulted in fatal disease [13]. Influenza wt H5N1 virus A/
OT/SZ/097/03 was isolated from an ostrich with fatal influenza
A H5N1 disease on a farm in 2004 in China. Depending on
sequence analysis and cladogram trees, A/OT/SZ/097/03
belongs to Clade 0. In our previous studies, data on antigenic
and genetic characteristics of A/OT/SZ/097/03 were reported
[14,15]. According to sequence analyses and cladogram trees,
remote antigenic distance exist between VN/1203, ID/05, AH/01
virus and A/OT/SZ/097/03. In this study, we produced
influenza H5N1 split vaccines with PR8/H5N1 6:2 reassortants
from isolates of different regions based on the three virus strains of
stockpile vaccines, A/Vietnam/1203/2004(Clade 1), A/Indone-
sia/05/2005(Clade 2.1), and A/Anhui/1/2005(Clade 2.3.4). A
mouse vaccination/challenge model was used to assess if this
composition with adjuvant could provide cross protection against a
lethal challenge with heterologous viruses of A/OT/SZ/097/
03(clade 0). Here, we compare the cross-protection efficacy of
single, multiple-clade H5N1 influenza vaccines given at 3 mgt oa
trivalent vaccine given at 1 mg of each virus. Following two
immunizations, mice were challenged with a wild type H5N1
virus. Immunological parameters (sIgA ELISA antibody; IFN-c
and IL-4 producing spleen cells) were followed. The key issue is
indeed the immunological parameters correlate with protection.
Of note, the single vaccines elicited stronger host immune
responses to the homologous antigens but less immune response
to the heterologous antigens than the trivalent vaccine (Figures 1
and 3), in spite of that the latter contained the same antigens as the
former. While the single vaccines also provided less protection
against wild type influenza virus A/OT/SZ/097/03 challenge
than trivalent vaccine (Figure 5). These results revealed that
different antigens of trivalent influenza vaccine could probably
overlap in immunogenicity and cross protection and different
antigens dose are uncertain equal. Thus, the trivalent vaccine
based on clade 1 and 2 was giving rise to a broadly cross-reactive
vaccine to potential prevention use ahead of the strain-specific
pandemic influenza vaccine in the event of an HPAI H5N1
influenza outbreak.
Cholera toxin (CT) and E. coli heat-labile enterotoxin are known
potent mucosal vaccine adjuvants and have been used in non-
clinical experimental systems. However, their clinical application
as nasal adjuvants had to be discontinued because of side effects
like Bell’s palsy [16]. Therefore, one of the major challenges in
adjuvant research is to gain potency while minimizing toxicity.
MF59, the first oil-in-water emulsion licensed as an adjuvant for
human use, can enhance vaccine immune responses through
multiple mechanisms [17,18]. It is worthy of note that the addition
of MF59 adjuvant induced a stronger cross-reactive immunity as
compared to non-adjuvanted multiple-clade vaccines [7]. A
trivalent MF59-adjuvanted seasonal influenza vaccine has shown
to induce significantly higher immune responses to influenza
vaccination in the elderly, compared with non-adjuvanted
vaccines, and to provide cross-reactive immunity against divergent
influenza strains. Similar results have been generated with a
MF59-adjuvanted H5N1 pre-pandemic vaccine, which showed
higher and broader immunogenicity compared with non-adju-
vanted pre-pandemic vaccines [7,18,19]. In contrast, we prepared
the oil-in-water emulsion adjuvant SP01 and found that mice
immunized intranasally with SP01 did not exhibit acute toxicity;
i.e., no cytokine-induced mortality, no obvious weight loss, no
abnormal behavior and no histopathological changes. In addition,
use of SP01 as a nasal adjuvant was safe and effective for inducing
remarkably systemic IgG and nasal sIgA Ab responses compared
with vaccine antigen alone[20]. Based on above results the single
clade and multiple-clade vaccines were tested just with oil-in-water
emulsion adjuvant SP01 to investigate this composition vaccine to
produce cross protection against heterologous virus challenge.
For development of mucosal vaccines both systemic and
mucosal immunity are important. For this reason, a suitable
approach would be to develop broad-spectrum virus strains as a
backbone; however, currently available single stockpiling influenza
virus vaccines are known to be insufficient when used for mucosal
immunization and the induction of cross protection [21,22].Ef-
fective H5N1 pandemic preparedness will require vaccines that
provide broad cross-protection and are readily available to large
groups of the population. However, intranasal delivery of the
trivalent vaccine could elicit a broader immune response than the
same vaccine delivered intramuscularly (data not shown).
Consistent with our previous studies, cellular responses, in
particular, were reduced in the pulmonary mucosa of mice
vaccinated i.m. as compared to i.n. vaccinated mice. The ability to
elicit mucosal immune responses in the respiratory tract, including
the lungs, is a desirable characteristic for an influenza vaccine [11].
Naive T-helper cells can differentiate into one of two subsets,
known as Th1 and Th2, depending on the context of the initial
stimulation they receive [23]. Th1 cells, which secrete IL-2, IFN-c,
and TNF-a, develop in the presence of IL-12. Th1 CD4
+ T-cells
activate CD8
+ T-cells and prime the cellular immune response.
IFN-c plays a crucial role in the clearance of influenza virus
infection via its ability to activate antibacterial functions of infected
macrophages. To investigate which subtype of cells is predominant
in mice, we examined the amount of IFN-c- and IL-4-producing
cells using an ELISPOT assay. The results show that VN/1203,
ID/05, AH/01, and trivalent vaccines could produce more IFN-c-
producing cells than IL-4-producing cells (Fig. 3). Influenza
vaccination seems predisposed to generate responses with a strong
bias toward TH1-type cellular immune responses because IFN-c is
mainly secreted by Th1 and CD8
+ T-cells. Our results indicate the
importance of Th1-type cellular immune responses in the
clearance of influenza viruses from an infected host.
Although some companies, like Baxter, do use inactivated wt
H5 viruses as vaccine, the production of H5N1 influenza vaccines
from a wt virus is generally not acceptable due to the attendant
risks and limited application. At present, several technologies are
under development for the production of H5N1 pandemic
vaccines that have shown promising clinical results. These include
vector vaccines, DNA vaccines, adjuvanted vaccines, ancestral
sequence reconstruction method and reverse genetics technology
[24–27]. Using reverse genetics, clinical trials of candidate H5N1
vaccines have been either initiated or completed. These include rg-
A/Vietnam/1203/2004(VN), rg-A/Indonesia/05/2005(ID), and
rg-A/Anhui/1/2005(AH) [24,25,28].
In conclusion, trivalent vaccines containing VN/1203, ID/05,
and AH/01 could elicit high immune responses, which provide
broader cross protection against lethal heterologus influenza virus
infection. The multiple-clade adjuvanted vaccine could be useful
in allowing timely initiation of vaccination against unknown
pandemic virus. Our findings also suggest that the multiple-clade
vaccination strategy appeared, at least in mice, to work successfully
for influenza infection and we propose the preferential stockpiling
of the pre-pandemic trivalent vaccines. Potential problems,
Influenza Vaccine Elicits Broad Cross Protection
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antigens, require further studies. Additionally, our findings prompt
further investigations of the effect of the multiple-clade H5N1
influenza vaccines in ferrets, monkeys and man.
Materials and Methods
Animals
We purchased 6- to 8-week-old female BALB/c mice from the
Laboratory Animal Center of the Academy of Military Medical
Sciences (AMMS), Beijing, China. Mice were kept under specific-
pathogen-free (SPF) conditions approved by the Institutional
Animal Care and Use Committee of the AMMS (ID: SYXK
2007-005). All operations with the wild-type virus A/OT/SZ/
097/03 was performed in biosafety level 3 animal facilities.
Viruses
Influenza vaccine strains rg-A/Vietnam/1203/2004, rg-A/
Indonesia/05/2005, and rg-A/Anhui/01/2005 (abbreviated
VN/1203, ID/05, and AH/01, respectively) were derived from
a recombinant avirulent avian virus containing modified HA and
neuraminidase NA genes of the wt H5N1 virus in the background
A/Puerto Rico/8/34. These vaccine strains were supplied by the
UK NIBSC and US Centers for Disease Control and Prevention.
The strain of HPAI H5N1 wt virus A/OT/SZ/097/03 (H5 HA
clade 0) (abbreviated China097), which was used as a challenge in
this study, was isolated and identified from fecal samples of a dead
ostrich on a farm at Yangzhou University in Jiangsu Province [14].
These viruses were propagated in 10-day-old embryonated
chicken eggs for 2 days at 35uC, and then stored at 280uC.
Virus titers were quantified by TCID50 assay using MDCK cells
(ATCC CCL-34) [29].
Preparation of vaccine
Influenza vaccine strains rg-A/Vietnam/1203/2004, rg-A/
Indonesia/05/2005, and rg-A/Anhui/1/2005 are pandemic vac-
cine strains recommended for use in vaccine development. The
vaccine was formulated and produced by Hualan Vaccine Inc.
(Henan, China) as influenza H5N1 split vaccines, with or without
adjuvant, and supplied in 0.5-ml pre-filled single-dose syringes.
Briefly, the virus vaccine was propagated in the allantoic cavity of
10-day-old SPF embryonating chicken eggs at 35uC. Allantoic
fluids were harvested 48 h after inoculation. Virus titers were de-
termined using HA assays. The vaccine was generated according
to standard techniques. The seed virus was grown to a high titer in
eggs and the virions were purified by centrifugation, inactivated
with formalin, and filtered to remove bacteria. Influenza H5N1
split vaccines were produced on a pilot scale under Good Manu-
facturing Practices. The HA protein content of the vaccines was
determined by the single radial immunodiffusion (SRID) method
[30]. Oil-in-water emulsion adjuvant SP01 containing squalene,
polyether and castor oil was added by mixing 1:1 v/v with the
vaccine.
Immunization and sample collection
Twenty-two mice for each experimental group were anesthe-
tized by intraperitoneal injection of 0.2 ml 2,2,2-tribromoetha-
nol in tert-amyl alcohol (Avertin; Sigma-Aldrich, St. Louis, MO)
and vaccinated i.n. with 3 mg influenza split vaccine (based on
HA content) in 20 ml phosphate-buffered saline (PBS) with an
adjuvant. Single vaccines (3 mg HA per dose) included VN/
1203, AH/01, and ID/05. The trivalent vaccine contained 1 mg
HA per dose of each single vaccine. SP01 adjuvants were used in
both primary and secondary vaccination [20]. Fourteen days
post-primary vaccination, mice were boosted with a second dose
of 3 mg H5N1 influenza split vaccine by the i.n. route with an
adjuvant. Six mice were killed on day 28 and blood was
collected. Meanwhile, lung, nasal cavity, and vaginal lavage were
collected for measurement of mucosal IgA and IgG titers as
described previously [31].
Hemagglutination inhibition (HI)
Serum samples were taken pretest, 2 weeks after the first
vaccination, and 2 weeks after the boost dose. Reference viruses
used for serologic testing were reverse genetics strains, and all
serological testing was performed in the BSL3+ containment
facility. Serum was treated with receptor-destroying enzyme
overnight at 37uC, heat-inactivated at 56uC for 45 min, diluted
1:10 with sterile PBS, and tested by hemagglutination inhibition
(HI) assay with 0.5% turkey erythrocytes [32]. The sera from mice
administrated PBS were used as negative controls. All assays were
performed in triplicate and repeated three times.
Preparation of splenocytes and ELISPOT assay
Two weeks after the final immunization, the spleens of dead
mice were removed under aseptic conditions. Single-cell suspen-
sions were prepared from the spleen, and the red blood cells were
lysed with red blood cell lysis buffer. Splenocytes were assayed
immediately at 37uCi n5 %C O 2 in RPM-1640 medium
supplemented with the appropriate heat-inactivated fetal calf
serum. The number of antibody-secreting cells (ASCs) was
evaluated in an enzyme-linked immunoSPOT assay (ELISPOT)
with the following modifications. ELISPOT plates were coated
overnight at 4uC, with 5 mg/ml split virus vaccine. Lymphocytes
(1610
5 cells) were added in duplicate and incubated overnight.
Antibodies (IgG, IgA, and IgM) secreted by the lymphocytes were
detected by incubation with biotin-labeled goat anti-mouse class-
specific antibodies for 2 h at room temperature. Following
development, the number of spots was counted using an
ImmunoSPOT series 3 automatic ELISPOT Reader.
To measure the amount of cytokine-producing cells, after 24 h
of stimulation in vitro with 7.5 mg/ml virus antigen, spleen cells
were tested for the presence of IFN-c and IL-4 by ELISPOT assay
using a BD TM mouse IFN-c and IL-4 ELISPOT set [33]. The
spot number corresponding to the IFN-c- and IL-4-producing cells
was calculated on an ELISPOT spot counter. All assays were
performed in triplicate and repeated three times.
Protection experiments
Ten mice for each experimental group were anaesthetized with
2,2,2-tribromoethanol in tert-amyl alcohol (Avertin; Sigma-Al-
drich, St. Louis, MO) and immunized intranasally with 3 mgH A
amount of vaccine with SP01 adjuvant. Two weeks later, they
were re-immunized in the same manner. Protection experiments
were performed by challenging mice with a nasal administration of
50LD50 A/OT/SZ/097/03 H5N1 virus 2 weeks after the last
immunization. Mice were followed 14 days after the infection, and
survival and weight loss were monitored. Lung tissues were
collected from euthanized mice on 4 day post-challenge for further
virological testing and histopathological analysis.
Viral titers
Immunized mice were challenged as described above and killed
on day 4 after virus inoculation. Nasal turbinates, lungs, spleen,
kidney and brains were harvested and homogenized in MEM
medium containing antibiotics to make a 10% w/v tissue
homogenates on day 4 post-infection (p.i.). Clarified tissue
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96-well culture plates containing MDCK cells, and titers were
expressed as log10TCID50/gram tissue [29].
Histopathological analysis
The lung tissues of challenged mice were immediately fixed in
10% neutral buffered formalin and embedded in paraffin wax.
Sections were made at 4–6 mm thickness and mounted on slides.
Histopathological changes were examined by H & E staining and
observed under light microscopy.
Statistical analyses
All data are shown as means 6 S.E.M. Measurements at single
timepoints were analyzed by an ANOVA, and if they demon-
strated significance, they were further analyzed by a two-tailed t-
test. All statistical tests were conducted using GraphPad Prism 5
software. p,0.05 indicates statistical significance.
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